European Patent Office Grants Metabolon Patent for Determining Metabolic Age of an Individual

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announced today the grant of EP Patent 2,089,539B entitled, “Biomarkers Related to Metabolic Age and Methods Using the Same.” The European Patent Office awarded the patent to Metabolon on December 7, 2011 and is the first patent issued to Metabolon by the EPO. The newly issued patent extends Metabolon’s intellectual property (IP) related to biomarkers of metabolic age; US7,781,160, the related United States Patent, was issued by the United States Patent and Trademark Office in August 2010.

As more information regarding the impact of nutrition on health-related issues becomes available and as the population ages, interest in health and nutrition has increased. The metabolism of an individual has been clinically shown to change with age, but until recently the ability to monitor metabolite changes has been limited to targeted assays. With the development of metabolomics analysis, changes in metabolites can now be monitored globally in a non-targeted manner. This approach allows a metabolic profile to be determined for a group or an individual by providing biomarkers and methods which can be used to determine their metabolic age. The profile will also allow for classification as a positive or negative and will provide guidance as to how to improve a negative profile and in effect, the individual’s health.

About Metabolon

Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon’s expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabolytics™, its biomarker discovery and analysis business, has completed over 320 client studies and processed over 30,000 samples for customers in 2010 alone. Building on its expertise in biochemistry understanding, Metabolon is also developing proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at [email protected] or 919-595-2200.



CONTACT:

LHA
Mackenzie Mills, 212-838-3777
[email protected]

KEYWORDS:   United States  Europe  North America  North Carolina

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.